Acadia Pharmaceuticals ACAD Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's other non-current liabilities?
- Acadia Pharmaceuticals (ACAD) reported other non-current liabilities of $12.64M in Q1 2026.
- How has Acadia Pharmaceuticals's other non-current liabilities changed year-over-year?
- Acadia Pharmaceuticals's other non-current liabilities decreased by 36.7% year-over-year, from $19.96M to $12.64M.
- What is the long-term trend for Acadia Pharmaceuticals's other non-current liabilities?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's other non-current liabilities has grown at a 29.9% compound annual growth rate (CAGR), from $5.18M to $19.14M.
- What does other non-current liabilities mean?
- Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.